
    
      In this phase II study, patients with solid tumors will receive treatment with intratumoral
      hiltonol and two cycles of autologous dendritic cells loaded with autologous tumor and
      administered subcutaneously. A new cohort will explore the role of radiation therapy, looking
      for an abscopal effect.
    
  